The two following stocks are on the list of the best stocks at this moment for their upward momentum of financial performance and good outlooks for future stock price appreciations.
RTI Biologics Inc.(RTIX) has a “Overweight” rating and a price target of $4.62 by seven analysts, according to the data provided by FactSet Research. The target represents a 25.54% upside potential for the current RTIX stock price of $3.68.
The company showed upward earnings momentum recently. For Q2 2012, the company reported EPS of 5 cents on revenue of $45.20 million, beating the average analyst estimate of 4 cents on $44.2 million. Gross margin, operating margin increased to 47.9% and 8.9%, representing advances of 2.6% and 1.9%, compared to the same period of last year, respectively. The company raised the expectation of the full fiscal year 2012 revenue to $177 million – $179 million, from the previously expected range of $176 million – $178 million; the full year net income of $0.14 to $0.15 per diluted share, as compared to prior guidance of $0.16 to $0.17 per diluted share. The guidance beat the analyst estimate of EPS of $0.17 on revenue of $177 million. For Q3 2012, the company expects EPS of $0.04 on revenue of $44 million to $45 million, topping the analyst estimate of $0.04 on revenue of 43 million.
The current RTIX stock price is 30.50% higher than its 52-week low of $2.82 and 23.17% off its 52-week high of $4.79. RITX stock is traded above its above its 50-day moving average of $3.61 while below its 200-day moving average of $3.89. RTI Biologics has a market cap of 205.47 million and a P/E multiple of 24.30.
Journal Communications, Inc. (JRN), one of the best stocks at this moment, has a “Overweight” rating and stock price target of $6.75 by four analysts, according to the data provided by FactSet Research. The target represents a 20.32% upside potential for the current JRN stock price of $5.61.
The company had a strong Q2 2012 results, seeing revenue up 6.0% to $95.5 million; operating income up 17.1%, to $13.5 million; EPS up 30% to $0.13, in line with the analyst estimate. The favorable results were driven by political and issue advertising and a continuing recovery in many of the local broadcast markets. Analysts at Benchmark Co. said the company’s strength in core broadcasting could drive a 17% year over year increase in total broadcast revenues. EBITDA could still increase 22% despite the rising costs. The company has acquired all 3,264,000 outstanding shares of its Class C common stock from the Grant family.The action reduced the total amount of outstanding shares and will have a positive effect on EPS.
JRN qualifys for one of the best stocks at this moment as its stock price has advanced 40.25% this year while the S&P 500 index moved up 11.64% during this period. The current JRN stock price is 108.55% higher than its 52-week low of $2.69 and 4.10% off its 52-week high of $5.85. JRN stock is traded above its above its 50-day moving average of $5.22 and 200-day moving average of $4.78. Journal Communications has a market cap of 301.88 million and a P/E multiple of 13.13.